 | • レポートコード：QYR2104Z1835 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、91ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、糖尿病性腎症のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ACE阻害薬、ARB、利尿薬、カルシウムチャネル遮断薬（CCB）、レニン阻害薬、結合組織成長因子（CTGF）阻害薬、抗酸化炎症調節薬（AIM）、単球化学誘引物質タンパク質（MCP）阻害薬、エンドセリンA受容体（ETAR）拮抗薬Gタンパク質共役型受容体（GPCR））、用途別市場規模（病院、がん研究所、診断研究所）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・糖尿病性腎症の市場動向 ・企業の競争状況、市場シェア ・糖尿病性腎症の種類別市場規模（ACE阻害薬、ARB、利尿薬、カルシウムチャネル遮断薬（CCB）、レニン阻害薬、結合組織成長因子（CTGF）阻害薬、抗酸化炎症調節薬（AIM）、単球化学誘引物質タンパク質（MCP）阻害薬、エンドセリンA受容体（ETAR）拮抗薬Gタンパク質共役型受容体（GPCR）） ・糖尿病性腎症の用途別市場規模（病院、がん研究所、診断研究所） ・糖尿病性腎症の北米市場規模2016-2027（アメリカ、カナダ） ・糖尿病性腎症のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・糖尿病性腎症のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・糖尿病性腎症の中南米市場規模2016-2027（メキシコ、ブラジル） ・糖尿病性腎症の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Novartis、Merck、Pfizer、Abbott Laboratories、Sanofi、Eli Lilly、AbbVie、Reata Pharmaceuticals、Bayer、Mitsubishi Tanabe Pharma） ・結論 |
Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Diabetic nephropathy is mainly characterized by macroalbuminuria. The presence of over 300 milligrams of albumin in the urine in 1 day is known as macroalbuminuria. Globally, the diabetic nephropathy market is witnessing significant growth due to rise in the incidence of diabetes and obesity in different regions of the world. In addition, increasing R&D investments in drug discovery and development by various companies, such as Sanofi, Eli Lilly and Mitsubishi Tanabe Pharma is also driving the growth of the market.
North America has the largest market for the global diabetic nephropathy market. However, In terms of growth, Asia is the fastest growing region. Disease Modifying Therapies (DMT) is the largest and fastest growing mode of treatment, whereas ACE inhibitors, is the largest and fastest growing DMT of diabetic nephropathy.
Market Analysis and Insights: Global Diabetic Nephropathy Market
The global Diabetic Nephropathy market size is projected to reach US$ 3337.8 million by 2026, from US$ 2398.5 million in 2019, at a CAGR of 4.8% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Diabetic Nephropathy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Diabetic Nephropathy market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Diabetic Nephropathy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Diabetic Nephropathy market.
Global Diabetic Nephropathy Scope and Market Size
Diabetic Nephropathy market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Diabetic Nephropathy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
ACE Inhibitors
ARBs
Diuretics
Calcium Channel Blockers(CCBs)
Renin Inhibitors
Connective Tissue Growth Factor (CTGF) Inhibitors
Antioxidant Inflammation Modulators(AIMs)
Monocyte Chemoattractant Protein (MCP)Inhibitors
Endothelin-A Receptor(ETAR)Antagonist
G Protein-Coupled Receptors (GPCRs)
Segment by Application
Hospitals
Cancer Research Institutes
Diagnostic Labs
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Novartis
Merck
Pfizer
Abbott Laboratories
Sanofi
Eli Lilly
AbbVie
Reata Pharmaceuticals
Bayer
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Diabetic Nephropathy Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 ACE Inhibitors
1.2.3 ARBs
1.2.4 Diuretics
1.2.5 Calcium Channel Blockers(CCBs)
1.2.6 Renin Inhibitors
1.2.7 Connective Tissue Growth Factor (CTGF) Inhibitors
1.2.8 Antioxidant Inflammation Modulators(AIMs)
1.2.9 Monocyte Chemoattractant Protein (MCP)Inhibitors
1.2.10 Endothelin-A Receptor(ETAR)Antagonist
1.2.11 G Protein-Coupled Receptors (GPCRs)
1.3 Market by Application
1.3.1 Global Diabetic Nephropathy Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Cancer Research Institutes
1.3.4 Diagnostic Labs
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Diabetic Nephropathy Market Perspective (2016-2027)
2.2 Diabetic Nephropathy Growth Trends by Regions
2.2.1 Diabetic Nephropathy Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Diabetic Nephropathy Historic Market Share by Regions (2016-2021)
2.2.3 Diabetic Nephropathy Forecasted Market Size by Regions (2022-2027)
2.3 Diabetic Nephropathy Industry Dynamic
2.3.1 Diabetic Nephropathy Market Trends
2.3.2 Diabetic Nephropathy Market Drivers
2.3.3 Diabetic Nephropathy Market Challenges
2.3.4 Diabetic Nephropathy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Diabetic Nephropathy Players by Revenue
3.1.1 Global Top Diabetic Nephropathy Players by Revenue (2016-2021)
3.1.2 Global Diabetic Nephropathy Revenue Market Share by Players (2016-2021)
3.2 Global Diabetic Nephropathy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Diabetic Nephropathy Revenue
3.4 Global Diabetic Nephropathy Market Concentration Ratio
3.4.1 Global Diabetic Nephropathy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Diabetic Nephropathy Revenue in 2020
3.5 Diabetic Nephropathy Key Players Head office and Area Served
3.6 Key Players Diabetic Nephropathy Product Solution and Service
3.7 Date of Enter into Diabetic Nephropathy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Diabetic Nephropathy Breakdown Data by Type
4.1 Global Diabetic Nephropathy Historic Market Size by Type (2016-2021)
4.2 Global Diabetic Nephropathy Forecasted Market Size by Type (2022-2027)
5 Diabetic Nephropathy Breakdown Data by Application
5.1 Global Diabetic Nephropathy Historic Market Size by Application (2016-2021)
5.2 Global Diabetic Nephropathy Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Diabetic Nephropathy Market Size (2016-2027)
6.2 North America Diabetic Nephropathy Market Size by Type
6.2.1 North America Diabetic Nephropathy Market Size by Type (2016-2021)
6.2.2 North America Diabetic Nephropathy Market Size by Type (2022-2027)
6.2.3 North America Diabetic Nephropathy Market Size by Type (2016-2027)
6.3 North America Diabetic Nephropathy Market Size by Application
6.3.1 North America Diabetic Nephropathy Market Size by Application (2016-2021)
6.3.2 North America Diabetic Nephropathy Market Size by Application (2022-2027)
6.3.3 North America Diabetic Nephropathy Market Size by Application (2016-2027)
6.4 North America Diabetic Nephropathy Market Size by Country
6.4.1 North America Diabetic Nephropathy Market Size by Country (2016-2021)
6.4.2 North America Diabetic Nephropathy Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Diabetic Nephropathy Market Size (2016-2027)
7.2 Europe Diabetic Nephropathy Market Size by Type
7.2.1 Europe Diabetic Nephropathy Market Size by Type (2016-2021)
7.2.2 Europe Diabetic Nephropathy Market Size by Type (2022-2027)
7.2.3 Europe Diabetic Nephropathy Market Size by Type (2016-2027)
7.3 Europe Diabetic Nephropathy Market Size by Application
7.3.1 Europe Diabetic Nephropathy Market Size by Application (2016-2021)
7.3.2 Europe Diabetic Nephropathy Market Size by Application (2022-2027)
7.3.3 Europe Diabetic Nephropathy Market Size by Application (2016-2027)
7.4 Europe Diabetic Nephropathy Market Size by Country
7.4.1 Europe Diabetic Nephropathy Market Size by Country (2016-2021)
7.4.2 Europe Diabetic Nephropathy Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Diabetic Nephropathy Market Size (2016-2027)
8.2 Asia-Pacific Diabetic Nephropathy Market Size by Type
8.2.1 Asia-Pacific Diabetic Nephropathy Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Diabetic Nephropathy Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Diabetic Nephropathy Market Size by Type (2016-2027)
8.3 Asia-Pacific Diabetic Nephropathy Market Size by Application
8.3.1 Asia-Pacific Diabetic Nephropathy Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Diabetic Nephropathy Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Diabetic Nephropathy Market Size by Application (2016-2027)
8.4 Asia-Pacific Diabetic Nephropathy Market Size by Region
8.4.1 Asia-Pacific Diabetic Nephropathy Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Diabetic Nephropathy Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Diabetic Nephropathy Market Size (2016-2027)
9.2 Latin America Diabetic Nephropathy Market Size by Type
9.2.1 Latin America Diabetic Nephropathy Market Size by Type (2016-2021)
9.2.2 Latin America Diabetic Nephropathy Market Size by Type (2022-2027)
9.2.3 Latin America Diabetic Nephropathy Market Size by Type (2016-2027)
9.3 Latin America Diabetic Nephropathy Market Size by Application
9.3.1 Latin America Diabetic Nephropathy Market Size by Application (2016-2021)
9.3.2 Latin America Diabetic Nephropathy Market Size by Application (2022-2027)
9.3.3 Latin America Diabetic Nephropathy Market Size by Application (2016-2027)
9.4 Latin America Diabetic Nephropathy Market Size by Country
9.4.1 Latin America Diabetic Nephropathy Market Size by Country (2016-2021)
9.4.2 Latin America Diabetic Nephropathy Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Diabetic Nephropathy Market Size (2016-2027)
10.2 Middle East & Africa Diabetic Nephropathy Market Size by Type
10.2.1 Middle East & Africa Diabetic Nephropathy Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Diabetic Nephropathy Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Diabetic Nephropathy Market Size by Type (2016-2027)
10.3 Middle East & Africa Diabetic Nephropathy Market Size by Application
10.3.1 Middle East & Africa Diabetic Nephropathy Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Diabetic Nephropathy Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Diabetic Nephropathy Market Size by Application (2016-2027)
10.4 Middle East & Africa Diabetic Nephropathy Market Size by Country
10.4.1 Middle East & Africa Diabetic Nephropathy Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Diabetic Nephropathy Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Diabetic Nephropathy Introduction
11.1.4 Novartis Revenue in Diabetic Nephropathy Business (2016-2021)
11.1.5 Novartis Recent Development
11.2 Merck
11.2.1 Merck Company Details
11.2.2 Merck Business Overview
11.2.3 Merck Diabetic Nephropathy Introduction
11.2.4 Merck Revenue in Diabetic Nephropathy Business (2016-2021)
11.2.5 Merck Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Diabetic Nephropathy Introduction
11.3.4 Pfizer Revenue in Diabetic Nephropathy Business (2016-2021)
11.3.5 Pfizer Recent Development
11.4 Abbott Laboratories
11.4.1 Abbott Laboratories Company Details
11.4.2 Abbott Laboratories Business Overview
11.4.3 Abbott Laboratories Diabetic Nephropathy Introduction
11.4.4 Abbott Laboratories Revenue in Diabetic Nephropathy Business (2016-2021)
11.4.5 Abbott Laboratories Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Details
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Diabetic Nephropathy Introduction
11.5.4 Sanofi Revenue in Diabetic Nephropathy Business (2016-2021)
11.5.5 Sanofi Recent Development
11.6 Eli Lilly
11.6.1 Eli Lilly Company Details
11.6.2 Eli Lilly Business Overview
11.6.3 Eli Lilly Diabetic Nephropathy Introduction
11.6.4 Eli Lilly Revenue in Diabetic Nephropathy Business (2016-2021)
11.6.5 Eli Lilly Recent Development
11.7 AbbVie
11.7.1 AbbVie Company Details
11.7.2 AbbVie Business Overview
11.7.3 AbbVie Diabetic Nephropathy Introduction
11.7.4 AbbVie Revenue in Diabetic Nephropathy Business (2016-2021)
11.7.5 AbbVie Recent Development
11.8 Reata Pharmaceuticals
11.8.1 Reata Pharmaceuticals Company Details
11.8.2 Reata Pharmaceuticals Business Overview
11.8.3 Reata Pharmaceuticals Diabetic Nephropathy Introduction
11.8.4 Reata Pharmaceuticals Revenue in Diabetic Nephropathy Business (2016-2021)
11.8.5 Reata Pharmaceuticals Recent Development
11.9 Bayer
11.9.1 Bayer Company Details
11.9.2 Bayer Business Overview
11.9.3 Bayer Diabetic Nephropathy Introduction
11.9.4 Bayer Revenue in Diabetic Nephropathy Business (2016-2021)
11.9.5 Bayer Recent Development
11.10 Mitsubishi Tanabe Pharma
11.10.1 Mitsubishi Tanabe Pharma Company Details
11.10.2 Mitsubishi Tanabe Pharma Business Overview
11.10.3 Mitsubishi Tanabe Pharma Diabetic Nephropathy Introduction
11.10.4 Mitsubishi Tanabe Pharma Revenue in Diabetic Nephropathy Business (2016-2021)
11.10.5 Mitsubishi Tanabe Pharma Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Diabetic Nephropathy Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of ACE Inhibitors
Table 3. Key Players of ARBs
Table 4. Key Players of Diuretics
Table 5. Key Players of Calcium Channel Blockers(CCBs)
Table 6. Key Players of Renin Inhibitors
Table 7. Key Players of Connective Tissue Growth Factor (CTGF) Inhibitors
Table 8. Key Players of Antioxidant Inflammation Modulators(AIMs)
Table 9. Key Players of Monocyte Chemoattractant Protein (MCP)Inhibitors
Table 10. Key Players of Endothelin-A Receptor(ETAR)Antagonist
Table 11. Key Players of G Protein-Coupled Receptors (GPCRs)
Table 12. Global Diabetic Nephropathy Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 13. Global Diabetic Nephropathy Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 14. Global Diabetic Nephropathy Market Size by Regions (2016-2021) & (US$ Million)
Table 15. Global Diabetic Nephropathy Market Share by Regions (2016-2021)
Table 16. Global Diabetic Nephropathy Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 17. Global Diabetic Nephropathy Market Share by Regions (2022-2027)
Table 18. Diabetic Nephropathy Market Trends
Table 19. Diabetic Nephropathy Market Drivers
Table 20. Diabetic Nephropathy Market Challenges
Table 21. Diabetic Nephropathy Market Restraints
Table 22. Global Diabetic Nephropathy Revenue by Players (2016-2021) & (US$ Million)
Table 23. Global Diabetic Nephropathy Market Share by Players (2016-2021)
Table 24. Global Top Diabetic Nephropathy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetic Nephropathy as of 2020)
Table 25. Ranking of Global Top Diabetic Nephropathy Companies by Revenue (US$ Million) in 2020
Table 26. Global 5 Largest Players Market Share by Diabetic Nephropathy Revenue (CR5 and HHI) & (2016-2021)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Diabetic Nephropathy Product Solution and Service
Table 29. Date of Enter into Diabetic Nephropathy Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Diabetic Nephropathy Market Size by Type (2016-2021) (US$ Million)
Table 32. Global Diabetic Nephropathy Revenue Market Share by Type (2016-2021)
Table 33. Global Diabetic Nephropathy Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 34. Global Diabetic Nephropathy Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 35. Global Diabetic Nephropathy Market Size Share by Application (2016-2021) & (US$ Million)
Table 36. Global Diabetic Nephropathy Revenue Market Share by Application (2016-2021)
Table 37. Global Diabetic Nephropathy Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 38. Global Diabetic Nephropathy Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 39. North America Diabetic Nephropathy Market Size by Type (2016-2021) (US$ Million)
Table 40. North America Diabetic Nephropathy Market Size by Type (2022-2027) & (US$ Million)
Table 41. North America Diabetic Nephropathy Market Size by Application (2016-2021) (US$ Million)
Table 42. North America Diabetic Nephropathy Market Size by Application (2022-2027) & (US$ Million)
Table 43. North America Diabetic Nephropathy Market Size by Country (2016-2021) & (US$ Million)
Table 44. North America Diabetic Nephropathy Market Size by Country (2022-2027) & (US$ Million)
Table 45. Europe Diabetic Nephropathy Market Size by Type (2016-2021) (US$ Million)
Table 46. Europe Diabetic Nephropathy Market Size by Type (2022-2027) & (US$ Million)
Table 47. Europe Diabetic Nephropathy Market Size by Application (2016-2021) (US$ Million)
Table 48. Europe Diabetic Nephropathy Market Size by Application (2022-2027) & (US$ Million)
Table 49. Europe Diabetic Nephropathy Market Size by Country (2016-2021) & (US$ Million)
Table 50. Europe Diabetic Nephropathy Market Size by Country (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Diabetic Nephropathy Market Size by Type (2016-2021) (US$ Million)
Table 52. Asia-Pacific Diabetic Nephropathy Market Size by Type (2022-2027) & (US$ Million)
Table 53. Asia-Pacific Diabetic Nephropathy Market Size by Application (2016-2021) (US$ Million)
Table 54. Asia-Pacific Diabetic Nephropathy Market Size by Application (2022-2027) & (US$ Million)
Table 55. Asia-Pacific Diabetic Nephropathy Market Size by Region (2016-2021) & (US$ Million)
Table 56. Asia-Pacific Diabetic Nephropathy Market Size by Region (2022-2027) & (US$ Million)
Table 57. Latin America Diabetic Nephropathy Market Size by Type (2016-2021) (US$ Million)
Table 58. Latin America Diabetic Nephropathy Market Size by Type (2022-2027) & (US$ Million)
Table 59. Latin America Diabetic Nephropathy Market Size by Application (2016-2021) (US$ Million)
Table 60. Latin America Diabetic Nephropathy Market Size by Application (2022-2027) & (US$ Million)
Table 61. Latin America Diabetic Nephropathy Market Size by Country (2016-2021) & (US$ Million)
Table 62. Latin America Diabetic Nephropathy Market Size by Country (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Diabetic Nephropathy Market Size by Type (2016-2021) (US$ Million)
Table 64. Middle East & Africa Diabetic Nephropathy Market Size by Type (2022-2027) & (US$ Million)
Table 65. Middle East & Africa Diabetic Nephropathy Market Size by Application (2016-2021) (US$ Million)
Table 66. Middle East & Africa Diabetic Nephropathy Market Size by Application (2022-2027) & (US$ Million)
Table 67. Middle East & Africa Diabetic Nephropathy Market Size by Country (2016-2021) & (US$ Million)
Table 68. Middle East & Africa Diabetic Nephropathy Market Size by Country (2022-2027) & (US$ Million)
Table 69. Novartis Company Details
Table 70. Novartis Business Overview
Table 71. Novartis Diabetic Nephropathy Product
Table 72. Novartis Revenue in Diabetic Nephropathy Business (2016-2021) & (US$ Million)
Table 73. Novartis Recent Development
Table 74. Merck Company Details
Table 75. Merck Business Overview
Table 76. Merck Diabetic Nephropathy Product
Table 77. Merck Revenue in Diabetic Nephropathy Business (2016-2021) & (US$ Million)
Table 78. Merck Recent Development
Table 79. Pfizer Company Details
Table 80. Pfizer Business Overview
Table 81. Pfizer Diabetic Nephropathy Product
Table 82. Pfizer Revenue in Diabetic Nephropathy Business (2016-2021) & (US$ Million)
Table 83. Pfizer Recent Development
Table 84. Abbott Laboratories Company Details
Table 85. Abbott Laboratories Business Overview
Table 86. Abbott Laboratories Diabetic Nephropathy Product
Table 87. Abbott Laboratories Revenue in Diabetic Nephropathy Business (2016-2021) & (US$ Million)
Table 88. Abbott Laboratories Recent Development
Table 89. Sanofi Company Details
Table 90. Sanofi Business Overview
Table 91. Sanofi Diabetic Nephropathy Product
Table 92. Sanofi Revenue in Diabetic Nephropathy Business (2016-2021) & (US$ Million)
Table 93. Sanofi Recent Development
Table 94. Eli Lilly Company Details
Table 95. Eli Lilly Business Overview
Table 96. Eli Lilly Diabetic Nephropathy Product
Table 97. Eli Lilly Revenue in Diabetic Nephropathy Business (2016-2021) & (US$ Million)
Table 98. Eli Lilly Recent Development
Table 99. AbbVie Company Details
Table 100. AbbVie Business Overview
Table 101. AbbVie Diabetic Nephropathy Product
Table 102. AbbVie Revenue in Diabetic Nephropathy Business (2016-2021) & (US$ Million)
Table 103. AbbVie Recent Development
Table 104. Reata Pharmaceuticals Company Details
Table 105. Reata Pharmaceuticals Business Overview
Table 106. Reata Pharmaceuticals Revenue in Diabetic Nephropathy Business (2016-2021) & (US$ Million)
Table 107. Reata Pharmaceuticals Recent Development
Table 108. Bayer Company Details
Table 109. Bayer Business Overview
Table 110. Bayer Diabetic Nephropathy Product
Table 111. Bayer Revenue in Diabetic Nephropathy Business (2016-2021) & (US$ Million)
Table 112. Bayer Recent Development
Table 113. Mitsubishi Tanabe Pharma Company Details
Table 114. Mitsubishi Tanabe Pharma Business Overview
Table 115. Mitsubishi Tanabe Pharma Diabetic Nephropathy Product
Table 116. Mitsubishi Tanabe Pharma Revenue in Diabetic Nephropathy Business (2016-2021) & (US$ Million)
Table 117. Mitsubishi Tanabe Pharma Recent Development
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Diabetic Nephropathy Market Share by Type: 2020 VS 2027
Figure 2. ACE Inhibitors Features
Figure 3. ARBs Features
Figure 4. Diuretics Features
Figure 5. Calcium Channel Blockers(CCBs) Features
Figure 6. Renin Inhibitors Features
Figure 7. Connective Tissue Growth Factor (CTGF) Inhibitors Features
Figure 8. Antioxidant Inflammation Modulators(AIMs) Features
Figure 9. Monocyte Chemoattractant Protein (MCP)Inhibitors Features
Figure 10. Endothelin-A Receptor(ETAR)Antagonist Features
Figure 11. G Protein-Coupled Receptors (GPCRs) Features
Figure 12. Global Diabetic Nephropathy Market Share by Application: 2020 VS 2027
Figure 13. Hospitals Case Studies
Figure 14. Cancer Research Institutes Case Studies
Figure 15. Diagnostic Labs Case Studies
Figure 16. Diabetic Nephropathy Report Years Considered
Figure 17. Global Diabetic Nephropathy Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 18. Global Diabetic Nephropathy Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 19. Global Diabetic Nephropathy Market Share by Regions: 2020 VS 2027
Figure 20. Global Diabetic Nephropathy Market Share by Regions (2022-2027)
Figure 21. Global Diabetic Nephropathy Market Share by Players in 2020
Figure 22. Global Top Diabetic Nephropathy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Diabetic Nephropathy as of 2020
Figure 23. The Top 10 and 5 Players Market Share by Diabetic Nephropathy Revenue in 2020
Figure 24. Global Diabetic Nephropathy Revenue Market Share by Type (2016-2021)
Figure 25. Global Diabetic Nephropathy Revenue Market Share by Type (2022-2027)
Figure 26. North America Diabetic Nephropathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. North America Diabetic Nephropathy Market Share by Type (2016-2027)
Figure 28. North America Diabetic Nephropathy Market Share by Application (2016-2027)
Figure 29. North America Diabetic Nephropathy Market Share by Country (2016-2027)
Figure 30. United States Diabetic Nephropathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Canada Diabetic Nephropathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Europe Diabetic Nephropathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Europe Diabetic Nephropathy Market Share by Type (2016-2027)
Figure 34. Europe Diabetic Nephropathy Market Share by Application (2016-2027)
Figure 35. Europe Diabetic Nephropathy Market Share by Country (2016-2027)
Figure 36. Germany Diabetic Nephropathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. France Diabetic Nephropathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. U.K. Diabetic Nephropathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Italy Diabetic Nephropathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Russia Diabetic Nephropathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Nordic Diabetic Nephropathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Asia-Pacific Diabetic Nephropathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Asia-Pacific Diabetic Nephropathy Market Share by Type (2016-2027)
Figure 44. Asia-Pacific Diabetic Nephropathy Market Share by Application (2016-2027)
Figure 45. Asia-Pacific Diabetic Nephropathy Market Share by Region (2016-2027)
Figure 46. China Diabetic Nephropathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Japan Diabetic Nephropathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. South Korea Diabetic Nephropathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Southeast Asia Diabetic Nephropathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. India Diabetic Nephropathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Australia Diabetic Nephropathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Latin America Diabetic Nephropathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Latin America Diabetic Nephropathy Market Share by Type (2016-2027)
Figure 54. Latin America Diabetic Nephropathy Market Share by Application (2016-2027)
Figure 55. Latin America Diabetic Nephropathy Market Share by Country (2016-2027)
Figure 56. Mexico Diabetic Nephropathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Brazil Diabetic Nephropathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Middle East & Africa Diabetic Nephropathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Middle East & Africa Diabetic Nephropathy Market Share by Type (2016-2027)
Figure 60. Middle East & Africa Diabetic Nephropathy Market Share by Application (2016-2027)
Figure 61. Middle East & Africa Diabetic Nephropathy Market Share by Country (2016-2027)
Figure 62. Turkey Diabetic Nephropathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 63. Saudi Arabia Diabetic Nephropathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 64. UAE Diabetic Nephropathy Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 65. Novartis Revenue Growth Rate in Diabetic Nephropathy Business (2016-2021)
Figure 66. Merck Revenue Growth Rate in Diabetic Nephropathy Business (2016-2021)
Figure 67. Pfizer Revenue Growth Rate in Diabetic Nephropathy Business (2016-2021)
Figure 68. Abbott Laboratories Revenue Growth Rate in Diabetic Nephropathy Business (2016-2021)
Figure 69. Sanofi Revenue Growth Rate in Diabetic Nephropathy Business (2016-2021)
Figure 70. Eli Lilly Revenue Growth Rate in Diabetic Nephropathy Business (2016-2021)
Figure 71. AbbVie Revenue Growth Rate in Diabetic Nephropathy Business (2016-2021)
Figure 72. Reata Pharmaceuticals Revenue Growth Rate in Diabetic Nephropathy Business (2016-2021)
Figure 73. Bayer Revenue Growth Rate in Diabetic Nephropathy Business (2016-2021)
Figure 74. Mitsubishi Tanabe Pharma Revenue Growth Rate in Diabetic Nephropathy Business (2016-2021)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed
世界の糖尿病性腎症市場規模・現状・予測（2021年-2027年） Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Diabetic nephropathy is mainly characterized by macroalbuminuria. The presence of over 300 milligrams of albumin in the urine in 1 …- 世界のGタンパク質共役型受容体（GPCR）市場規模・現状・予測（2021年-2027年） G protein–coupled receptors ( GPCRs ) which are also known as seven-transmembrane domain receptors , 7TM receptors , heptahelical receptors , serpentine receptor , and G protein–linked receptors ( GPLR ), constitute a large protein family of receptors , that detect molecules outside the cell and act…
- 世界のGタンパク質共役型受容体市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global G-protein Coupled Receptor Market The global G-protein Coupled Receptor market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, …
- 世界のTNF阻害剤市場規模・現状・予測（2021年-2027年） TNF (tumor necrosis factor) inhibitors are anti-inflammatory drugs. TNF inhibitors help to block the TNF alpha that occurs naturally in the body and causes inflammation. TNF drugs are used to reduce inflammation and stop disease progression by targeting the tumor necrosis factor, which is an inflamm…
- 世界のシグナル伝達阻害剤市場規模・現状・予測（2021年-2027年） Signal transduction inhibitors are drugs that may prevent the ability of cancer cells to multiply quickly and invade other tissues. Growing need for effective cancer diagnostics and innovative therapies for cancer treatment are expected to be the major factors driving the signal transduction inhibit…